Blueprint Medicines Corporation (NASDAQ:BPMC) Stake Raised by Cwm LLC

CWM LLC grew its holdings in shares of Blueprint Medicines Corporation (NASDAQ:BPMC - Free Report) by 62.3% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 5,321 shares of the biotechnology company's stock after purchasing an additional 2,042 shares during the quarter. CWM LLC's holdings in Blueprint Medicines were worth $471,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in BPMC. Vanguard Group Inc. raised its position in shares of Blueprint Medicines by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 6,774,884 shares of the biotechnology company's stock worth $590,905,000 after buying an additional 91,450 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in Blueprint Medicines by 5.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,679,089 shares of the biotechnology company's stock valued at $495,331,000 after purchasing an additional 291,822 shares in the last quarter. Wellington Management Group LLP increased its holdings in Blueprint Medicines by 8.0% in the 4th quarter. Wellington Management Group LLP now owns 4,281,364 shares of the biotechnology company's stock valued at $373,421,000 after purchasing an additional 316,754 shares in the last quarter. Geode Capital Management LLC increased its holdings in Blueprint Medicines by 0.7% in the 4th quarter. Geode Capital Management LLC now owns 1,490,101 shares of the biotechnology company's stock valued at $129,996,000 after purchasing an additional 9,914 shares in the last quarter. Finally, Avoro Capital Advisors LLC acquired a new stake in Blueprint Medicines in the 4th quarter valued at $103,356,000.

Blueprint Medicines Stock Performance

Shares of BPMC stock remained flat at $129.46 during trading hours on Monday. The company has a debt-to-equity ratio of 1.01, a quick ratio of 2.75 and a current ratio of 2.80. Blueprint Medicines Corporation has a 12-month low of $73.04 and a 12-month high of $129.65. The firm has a 50-day moving average of $123.55 and a 200 day moving average of $105.01. The firm has a market cap of $8.36 billion, a PE ratio of -52.41 and a beta of 0.89.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.32). Blueprint Medicines had a negative return on equity of 64.60% and a negative net margin of 27.70%. The company had revenue of $149.41 million for the quarter, compared to the consensus estimate of $158.31 million. During the same period in the previous year, the business posted $1.40 EPS. The business's revenue for the quarter was up 55.5% on a year-over-year basis. On average, equities research analysts forecast that Blueprint Medicines Corporation will post -1.28 EPS for the current year.

Insider Buying and Selling at Blueprint Medicines

In other Blueprint Medicines news, insider Ariel Hurley sold 2,752 shares of the firm's stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $103.13, for a total value of $283,813.76. Following the transaction, the insider owned 16,944 shares of the company's stock, valued at $1,747,434.72. This trade represents a 13.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Percy H. Carter sold 1,051 shares of the firm's stock in a transaction dated Thursday, July 3rd. The stock was sold at an average price of $128.25, for a total transaction of $134,790.75. Following the completion of the transaction, the insider directly owned 53,155 shares in the company, valued at $6,817,128.75. This represents a 1.94% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 13,351 shares of company stock worth $1,384,244. Insiders own 4.21% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on BPMC. JPMorgan Chase & Co. reiterated a "neutral" rating and issued a $129.00 price target (down from $130.00) on shares of Blueprint Medicines in a report on Monday, June 2nd. Cowen downgraded Blueprint Medicines to a "hold" rating in a report on Monday, June 2nd. Stephens downgraded Blueprint Medicines from a "strong-buy" rating to a "hold" rating and lowered their price target for the company from $150.00 to $135.00 in a report on Tuesday, June 3rd. Citizens Jmp downgraded Blueprint Medicines from a "strong-buy" rating to a "hold" rating in a report on Tuesday, June 3rd. Finally, HC Wainwright reiterated a "buy" rating and issued a $135.00 price target on shares of Blueprint Medicines in a report on Friday, May 2nd. Eighteen analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $128.25.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.